The Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The castrate resistant prostate cancer market comprises drugs used for treatment of prostate cancer that has spread to other parts of the body even...
Prostate cancer is one of the most common types of cancer found in men. It usually grows slowly and initially remains confined to the prostate gland, where it may not cause serious harm. However, in some cases it grows large enough to spread outside the prostate or come back after treatment. Castrate resistant prostate cancer (CRPC) occurs when the cancer continues to grow and spread even when...
Market Overview:Castrate-resistant prostate cancer (CRPC) refers to prostate cancer that continues to grow even after the medical or surgical castration treatment of prostate cancer. It occurs when prostate cancer no longer respond to hormonal therapy and it begins to spread further. The treatment options for CRPC includes chemotherapy, radiotherapy, targeted therapy and immunotherapy.Market...
The global Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.Market Overview:Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that does not...